New insight into A1 adenosine receptors in diabetes treatment

Current Pharmaceutical Design

Volumn 16, Issue 38, 2010, Pages 4237-4242

  Wojcik, Marzena ^a   Zieleniak, Andrzej ^a   Wozniak, Lucyna A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adenosine receptors; Agonists; Antagonists; Diabetes; Insulin resistance; Lipolysis

Indexed keywords

3 METHOXYMETHYL 5 [6 [1 (5 TRIFLUOROMETHYL PYRIDIN 2 YL)PYRROLIDIN 3 [S] YLAMINO] PURIN 9 YL]CYCLOPENTANE 1,2 DIOL); 5 N ETHYLCARBOXAMIDOADENOSINE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N CYCLOHEXYL 2' O METHYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; ADENINE NUCLEOTIDE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; BW A1433U; CAFFEINE; CVT 3619; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PSB 1115; PSB 115; PSB 53; RG 14202; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST;

ARTICLE; COFFEE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYDROLYSIS; INSULIN RESISTANCE; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; ANIMAL; CARBOHYDRATE METABOLISM; CHEMISTRY; DIABETES MELLITUS; DRUG EFFECT; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; REVIEW;

ADENOSINE A1 RECEPTOR AGONISTS; ADENOSINE A1 RECEPTOR ANTAGONISTS; ANIMALS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; HUMANS; LIPID METABOLISM; RECEPTOR, ADENOSINE A1;

EID: 79951717184     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519066     Document Type: Article

References (62)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004; 27: 1047-53.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
3. Sandoval DA, Obici S, Seeley RJ. Targeting the CNS to treat type2 diabetes. Nat Rev Drug Discov 2009; 8: 386-98.
4. Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 2010; 204: 1-11.
5. Weinstein AR, Sesso HD, Lee IM, et al. Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA 2004; 292: 1188-94.
6. Bajaj M, DeFronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003; 10: 311-23.
7. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; (Suppl.3): 14-23.
8. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998; 24: 409-18.
9. Schwabe U, Schonhofer PS, Ebert R. Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3', 5'- monophosphate, lipolysis, and glucose oxidation in isolated fat cells. Eur J Biochem 1974; 46: 537-45.
10. Dong Q, Ginsberg HN, Erlanger BF. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesityrelated insulin resistance. Diabetes Obes Metab 2001; 3: 360-6.
11. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-78.
12. Hutchinson SA, Scammels PJ. A1 adenosine receptor agonists: medicinal chemistry and therapeutic potential. Curr Pharm Des 2004; 10: 2021-39.
13. Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008; 108: 238-63.
14. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 364-74.
15. Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996; 118: 1461-8.
16. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 1993; 90: 10365-9.
17. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-2.
18. Zimmermann H. Ectonucleotidases: some development and a note on nomenclature. Drug Dev Res 2001; 52: 44-56.
19. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5'- nucleotidase and nonspecific alkaline phosphatase. Two AMPhydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 2003; 278: 13468-79.
20. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
21. Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol 2009; 7: 426-34.
22. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIFdependent induction of adenosine A2B receptor in hypoxia. FASEB J 2006; 20: 2242-50.
23. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5: 247-64.
24. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008; 117: 123-40.
25. Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol Rev 1997; 49: 381-402.
26. Yasuda N, Inoue T, Horizoe T, et al. Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. Eur J Pharmacol 2003; 459: 159-66.
27. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A2B adenosine receptors in immunity and inflammation. Trends Immunol 2009; 30: 263-70.
28. Simola N, Morelli M, Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 2008; 14: 1475-89.
29. Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. A1 adenosine receptor: role in diabetes and obesity. Handb Exp Pharmacol 2009; 193: 271-95.
30. Lin Z, Yin P, Reierstad S, et al. Adenosine A1 receptor, a target and regulator of estrogen receptor alpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene 2010; 29: 1114-22.
31. Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007; 12: 479-92.
32. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Emerg Drugs 2008; 17: 1901-10.
33. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein- mediated signalling and the role of accessory proteins. Cell Signal 2002; 14: 99-108.
34. Strong P, Anderson R, Coates J, et al. Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin Sci (Lond) 1993; 84: 663-9.
35. Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-Omethyl- adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res Clin Pract 1998; 39: 3-9.
36. Schoelch C, Kuhlmann J, Gossel M, et al. Characterization of adenosine-A1 receptor-mediated antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp studies. Diabetes 2004; 53: 1920-6.
37. Wagner H, Milavec-Krizman M, Gradient F, et al. General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev Res 1995; 34: 276-88.
38. Cox BF, Clark KL, Perrone MH, et al. Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocintreated rats. J Cardiovasc Pharmacol 1997; 29: 417-26.
39. Qu X, Cooney G, Donnelly R. Short-term metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats. Eur J Pharmacol 1997; 338: 269-76.
40. Zannikos PN, Rohatagi S, Jensen BK. Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. J Clin Pharmacol 2001; 41: 61-9.
41. Cheng JT, Chi TC, Liu IM. Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton Neurosci 2000; 83: 127-33.
42. Töpfer M, Burbiel CE, Müller CE, Knittel J, Verspohl EJ. Modulation of insulin release by adenosine A1 receptor agonists and antagonists in INS-1 cells: the possible contribution of 86Rb+ efflux and 45Ca2+ uptake. Cell Biochem Funct 2008; 26: 833-43.
43. Rüsing D, Müller CE, Verspohl EJ. The impact of adenosine and A(2B) receptors on glucose homoeostasis. J Pharm Pharmacol 2006; 58: 1639-45.
44. Fatholahi M, Xiang Y, Wu Y, et al. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006; 317: 676-84.
45. Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 2007; 292: E1358-63.
46. Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther 2009; 328: 306-11.
47. Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli LJ. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 2007; 321: 327-33.
48. Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab 2009; 11: 95-101.
49. Poulsen SA, Quinn RJ. Adenosine receptors: new opportunites for future drugs. Bioorg Med Chem 1998; 6: 619-41.
50. Pimentel GD, Zemdegs JCS, Theodoro JA, Mota JF. Does long term coffee intake reduce type 2 diabetes mellitus risk? Diabetol Metab Syndr 2009; 1: 6.
51. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005; 294: 97-104.
52. van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 2009; 32: 1023-5.
53. Bruns RF, Fergus JH, Badger EW, et al. Binding of the A1- selective adenosine antagonist, 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunym-Schmiedeberg's Arch Pharmacol 1987; 335: 59-63.
54. Szkudelski T, Szkudelska K, Notowski L. Effects of adenosine A1 receptor antagonism on lipogenesis and lipolysis in isolated rat adipocytes. Physiol Res 2009; 58: 863-71.
55. Linden J. Structure and function of A1 adenosine receptors. FASEB J 1991; 5: 2668-76.
56. Wang J, Drake L, Sajjadi F, Firestein GS, Mullane K.M, Bullough DA. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997; 320: 241-8.
57. Xu B, Berkich DA, Crist GH, LaNoue KF. A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. Am J Physiol 1998; 274: E271-9.
58. Crist GH, Xu B, LaNoue KF, Lang CH. Tissue-specific effects of in vivo adenosine receptor blockade on glucose uptake in Zucker rats. FASEB J 1998; 12: 1301-8.
59. Grden M, Podgorska M, Szutowicz A, Pawelczyk T. Diabetesinduced alterations of adenosine receptors expression level in rat liver. Exp Mol Pathol 2007; 83: 392-8.
60. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Protein kinase C mediated high glucose effect on adenosine receptors expression in rat B lymphocytes. J Physiol Pharmacol 2009; 60: 145-53.
61. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Regulation of adenosine receptors expression in rat B lymphocytes by insulin. J Cell Biochem 2010; 109: 396-405.
62. Nemeth ZH, Bleich D, Csoka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007; 21: 2379-88.